A detailed history of Heartland Bank & Trust CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Heartland Bank & Trust CO holds 910 shares of REGN stock, worth $956,437. This represents 0.52% of its overall portfolio holdings.

Number of Shares
910
Previous 906 0.44%
Holding current value
$956,437
Previous $795,000 10.06%
% of portfolio
0.52%
Previous 0.55%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 17, 2024

BUY
$902.69 - $993.35 $3,610 - $3,973
4 Added 0.44%
910 $875,000
Q4 2023

Jan 23, 2024

SELL
$775.18 - $881.7 $66,665 - $75,826
-86 Reduced 8.67%
906 $795,000
Q3 2023

Oct 12, 2023

BUY
$692.45 - $844.37 $60,243 - $73,460
87 Added 9.61%
992 $816,000
Q2 2023

Jul 19, 2023

BUY
$700.03 - $830.35 $336,014 - $398,568
480 Added 112.94%
905 $650,000
Q1 2023

Apr 17, 2023

SELL
$680.49 - $826.97 $369,506 - $449,044
-543 Reduced 56.1%
425 $349,000
Q4 2022

Feb 09, 2023

BUY
$705.89 - $766.39 $705 - $766
1 Added 0.1%
968 $698,000
Q3 2022

Oct 11, 2022

SELL
$573.97 - $724.32 $77,485 - $97,783
-135 Reduced 12.25%
967 $666,000
Q2 2022

Jul 12, 2022

BUY
$548.35 - $738.84 $37,287 - $50,241
68 Added 6.58%
1,102 $651,000
Q1 2022

Apr 12, 2022

BUY
$595.12 - $698.43 $423,130 - $496,583
711 Added 220.12%
1,034 $722,000
Q4 2021

Feb 04, 2022

BUY
$543.48 - $670.97 $175,544 - $216,723
323 New
323 $204,000
Q2 2021

Jul 30, 2021

SELL
$472.8 - $558.54 $767,354 - $906,510
-1,623 Closed
0 $0
Q1 2021

Jun 21, 2021

BUY
$446.73 - $548.2 $254,636 - $312,474
570 Added 54.13%
1,623 $768,000
Q4 2020

Jun 15, 2021

BUY
$478.3 - $607.98 $503,649 - $640,202
1,053 New
1,053 $509,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $113B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Heartland Bank & Trust CO Portfolio

Follow Heartland Bank & Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Heartland Bank & Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Heartland Bank & Trust CO with notifications on news.